Novel Donor Site Dressing (Product X)

Burns Clinical Trial

Official title:

A Phase I/II Randomized Trial to Determine the Safety of a Novel Donor Site Dressing (Product X)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06163742
• Other study ID #: 16307
• Status: Not yet recruiting
• Phase: N/A
• Start date: April 2024
• Est. completion date: April 2026

Study information

• Verified date: February 2024
• Source: Hamilton Health Sciences Corporation
• Contact: Marc G Jeschke, MD PhD
• Phone: 9055212100
• Email: marc.jeschke[@]hhsc.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to test a novel donor site dressing called Product X in burn patients requiring skin grafting procedures. A donor site is an area where the surgeon has taken a layer of skin to create a graft. This is required to make severe burn wounds heal. However, donor sites often experience infection, pain, and itch that can delay the healing of the donor site. To prevent these complications, donor sites are covered with dressings to prevent infection and absorb fluids from the wounds. Many options exist, but no single dressing is best, especially for pain management and the ability to absorb fluids from wounds effectively.

The investigators have developed a new donor site dressing to meet the criteria of an "ideal dressing," called Product X. The main question this clinical trial aims to determine the safety and potential wound-healing benefits of this donor site dressing as a new therapy that will help patients who require donor sites.

Participants will:

• Be randomized, like a flip of a coin, to receive either Product X or the standard-of-care dressings. If patients have one donor site, it will be randomized to receive either Product X or the standard-of-care dressings, Allevyn and Xeroform. If they have two donor sites, one donor site will be randomized to receive Product X and the other to receive standard-of-care dressings.

• Have photographs of their donor sites taken at the operation, during dressing changes, at discharge, and at regularly scheduled outpatient follow-up appointments with the burn clinic.

• Complete short questionnaires to assess their comfort (pain and itch) with their donor sites daily.

• Complete a scar formation questionnaire at your regularly scheduled follow-up appointments in the outpatient burn clinic.

Researchers will compare Product X to standard-of-care dressings (Allevyn and Xeroform) to see if there are improvements in wound healing, pain, itch, and infection.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 40
• Est. completion date: April 2026
• Est. primary completion date: October 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. =18 years of age;

2. <25% total body surface area (TBSA) burn;

3. Deep partial or full-thickness burn requiring operative procedures;

4. Autologous donor site(s) on thigh, torso, and/or arm.

Exclusion Criteria:

1. Patients who are moribund.

2. Pregnancy.

3. Active cancer and currently undergoing treatment.

Related Conditions & MeSH terms

• Burns

Intervention

Device:
• Product X
The investigational device is a polyethylene glycol-based biomaterial. It can be applied to donor sites on the arms, torso, and legs.
• Standard-of-Care
The active comparator includes the current standard-of-care treatment: hydrocellular polyurethane dressing covered with TegadermTM film for 48 hours, followed by an occlusive gauze impregnated with 3% Bismuth Tribromorphenate in petrolatum.

Locations

Country	Name	City	State
Canada	Hamilton General Hospital	Hamilton	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Hamilton Health Sciences Corporation

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of donor site infections	Donor site infection requiring antibiotic/antifungal treatment or additional (unplanned) OR.	From date of donor site dressing application until date of hospital discharge, assessed up to 52 weeks.
Primary	Number of non-healing donor sites	Non-healing donor site requiring additional (unplanned) OR.	From date of donor site dressing application until date of hospital discharge, assessed up to 52 weeks.
Primary	Poor scarring requiring additional (unplanned) OR measured with the Patient Observer Scar Assessment Score (POSAS).	Scores will range from 1 to 10 for each measure, with higher scores indicating worse scarring.	At 3 months and 6 months post-hospital discharge.
Secondary	The amount of excess bleeding from the donor site measured by the need for interventions to control the bleeding.		From date of donor site dressing application until last dressing takedown, assessed up to 52 weeks.
Secondary	Time from autografting procedure to 95% healing of donor site.	Photography and evaluation of the donor site at operation, dressing-take downs, and discharge from the hospital.	From date of donor site dressing application until hospital discharge, assessed up to 52 weeks.
Secondary	Scar formation over time using the Patient and Observer Scar Assessment Scale	Scores will range from 1 to 10 for each measure, with higher scores indicating worse scarring.	At 3 months and 6 months post-hospital discharge.
Secondary	Absorption of wound exudate measured daily by the amount of dressing required and the number of additional dressing changes needed.	Greater amounts of dressings required and greater numbers of dressing changes indicate worse absorbability.	From application of the donor site dressing until last dressing takedown, assessed up to 52 weeks.
Secondary	Number of patients experiencing adhesion of the dressing to the donor site	Adhesion of the dressing to the donor site will be measured as: no adhesion, partial adhesion, or adhesion of the dressing to the donor site, with adhesion of the dressing to the donor site area having worse outcomes.	From application of the donor site dressing until last dressing takedown, assessed up to 52 weeks.
Secondary	Range of motion of the donor site measured by the ability to actively participate in therapy sessions.	Assessed in terms of the patient's subjective limitations in moving the donor site area. Measured as either: no limitations, minimal limitations, moderate limitations, or severe limitations in movement, with severe limitations being the worst outcome, indicating very limited movement of the donor site area.	From application of the donor site dressing until last dressing takedown, assessed up to 52 weeks.
Secondary	Donor Site Pain	Subjective donor site pain will be evaluated within 24 hours of each dressing change by participants using the Numeric Pain Scale. The Numeric Pain Scale ranges from 0 (no pain) to 10 (severe pain).	From application of the donor site dressing until last dressing takedown, assessed up to 52 weeks.
Secondary	Itch	Subjective measures of the presence and severity of itch will be measured daily by patients using the ItchyQuant scale, a validated numeric itch scale. The scale ranges from 0 (no itch) to 10 (severe itch).	From application of the donor site dressing until last dressing takedown, assessed up to 52 weeks.